Medincell Provides Update on Phase 3 mdc-CWM Clinical Trial
May 14, 2024
May 14, 2024
Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia
May 8, 2024
May 8, 2024
[Replay] Videoconference • Collaboration with AbbVie (French)
April 17, 2024
April 17, 2024
Medincell enters into strategic co-development and licensing agreement with AbbVie to develop next-generation long-acting injectable therapies
April 16, 2024
April 16, 2024
[Replay] Medincell Presentation at the 23rd Annual Needham Virtual Healthcare Conference
April 11, 2024
April 11, 2024
Unitaid Awards Medincell up to $6 million Extension Grant to Fight Malaria
April 8, 2024
April 8, 2024
Pharmaceutical Industry Veteran Strategist Philippe Guy Becomes Chairman of MedinCell’s Supervisory Board
March 13, 2024
March 13, 2024
[Replay] Medincell Presentation at Evercore ISI 2024 Emerging Biotech Conference
February 28, 2024
February 28, 2024
MedinCell’s partner Teva provides guidance for UZEDY in 2024 and an update on olanzapine LAI (mdc-TJK)
January 31, 2024
January 31, 2024
Teva announces recruitment completion of phase 3 clinical study of mdc-TJK
